| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ... New England Journal of Medicine 379 (26), 2495-2505, 2018 | 2370 | 2018 |
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial … C Aghajanian, SV Blank, BA Goff, PL Judson, MG Teneriello, A Husain, ... Journal of clinical oncology 30 (17), 2039, 2012 | 1642 | 2012 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1584 | 2017 |
| Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ... Journal of Clinical Oncology 20 (12), 2824-2831, 2002 | 809 | 2002 |
| Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ... New England Journal of Medicine 381 (25), 2403-2415, 2019 | 766 | 2019 |
| Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm DS Chi, EL Eisenhauer, O Zivanovic, Y Sonoda, NR Abu-Rustum, ... Gynecologic oncology 114 (1), 26-31, 2009 | 691 | 2009 |
| A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ... Clinical cancer research 8 (8), 2505-2511, 2002 | 611 | 2002 |
| The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center NR Abu-Rustum, K Alektiar, A Iasonos, G Lev, Y Sonoda, C Aghajanian, ... Gynecologic oncology 103 (2), 714-718, 2006 | 462 | 2006 |
| Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ... Cell 170 (5), 927-938. e20, 2017 | 443 | 2017 |
| Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial V Makker, D Rasco, NJ Vogelzang, MS Brose, AL Cohn, J Mier, ... The Lancet Oncology 20 (5), 711-718, 2019 | 435 | 2019 |
| Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma DS Chi, K McCaughty, JP Diaz, J Huh, S Schwabenbauer, AJ Hummer, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 432 | 2006 |
| Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer V Makker, MH Taylor, C Aghajanian, A Oaknin, J Mier, AL Cohn, ... Journal of clinical oncology 38 (26), 2981-2992, 2020 | 430 | 2020 |
| The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer EL Eisenhauer, NR Abu-Rustum, Y Sonoda, DA Levine, EA Poynor, ... Gynecologic oncology 103 (3), 1083-1090, 2006 | 416 | 2006 |
| Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer KS Tewari, RA Burger, D Enserro, BM Norquist, EM Swisher, MF Brady, ... Journal of Clinical Oncology 37 (26), 2317, 2019 | 385 | 2019 |
| Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study C Aghajanian, MW Sill, KM Darcy, B Greer, DS McMeekin, PG Rose, ... Journal of clinical oncology 29 (16), 2259, 2011 | 368 | 2011 |
| Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer C Aghajanian, B Goff, LR Nycum, YV Wang, A Husain, SV Blank Gynecologic oncology 139 (1), 10-16, 2015 | 343 | 2015 |
| Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ... Clinical cancer research 18 (23), 6497-6508, 2012 | 317 | 2012 |
| Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. D Fennelly, C Aghajanian, F Shapiro, C O'flaherty, M McKenzie, ... Journal of Clinical Oncology 15 (1), 187-192, 1997 | 309 | 1997 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 307 | 2015 |
| Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ... Gynecologic oncology 140 (2), 199-203, 2016 | 302 | 2016 |
